中医药对糖尿病性骨质疏松症的防治作用及机制探讨
Preventive and Therapeutic Effect of Traditional Chinese Medicine on Diabetes Osteoporosis and Its Mechanism
DOI: 10.12677/tcm.2025.141065, PDF,   
作者: 肖 巍, 蔡萧君：黑龙江省中医药科学院，黑龙江 哈尔滨
关键词: 糖尿病性骨质疏松症；中医药；防治作用；Diabetic Osteoporosis； Traditional Chinese Medicine； Preventive Effect
摘要: 糖尿病性骨质疏松症(DOP)是糖尿病患者常见的并发症，其主要特征为骨密度降低、骨微结构破坏和骨折风险增加。这种病症不仅增加了患者的生活负担，还显著影响了生活质量，并给医疗系统带来了沉重压力。随着全球糖尿病患病率的持续上升，DOP的防治需求愈加迫切。中医药在调理慢性病和增强体质方面具有独特优势，尤其适合复杂慢性病的管理。中医药通过调节糖代谢、骨代谢以及抗炎、抗氧化和免疫调节等多重作用，在防治DOP方面展现出良好的疗效。研究旨在系统探讨中医药在DOP防治中的作用及具体机制。通过总结和分析现有的临床与实验研究，验证传统中药方剂、单味中药及中医外治法在DOP防治中的有效性。深入研究中医药调节糖代谢、骨代谢的具体途径，揭示其在整体干预DOP病程中的作用机制。
Abstract: Diabetic osteoporosis (DOP) is a common complication in patients with diabetes mellitus, which is characterized by reduced bone mineral density, destruction of bone microstructure and increased risk of fracture. This condition not only increases the burden of living for patients, but also significantly affects quality of life and puts a heavy strain on the healthcare system. As the prevalence of diabetes mellitus continues to rise globally, the need for DOP prevention and treatment is becoming more urgent. Traditional Chinese medicine (TCM) has unique advantages in regulating chronic diseases and enhancing physical fitness, and is particularly suitable for the management of complex chronic diseases. TCM has shown good efficacy in the prevention and treatment of DOP by regulating glucose metabolism, bone metabolism, and the multiple effects of anti-inflammatory, antioxidant and immunomodulation. The study aims to systematically investigate the role and specific mechanisms of TCM in the prevention and treatment of DOP. By summarizing and analyzing the existing clinical and experimental studies, the effectiveness of traditional Chinese medicine formulas, single-flavour Chinese medicines and external Chinese medicine treatments in the prevention and treatment of DOP will be verified. The specific pathways of TCM in regulating glucose metabolism and bone metabolism were studied in depth to reveal its mechanism of action in the overall intervention of DOP disease process.
文章引用：肖巍, 蔡萧君. 中医药对糖尿病性骨质疏松症的防治作用及机制探讨[J]. 中医学, 2025, 14(1): 441-447. https://doi.org/10.12677/tcm.2025.141065

参考文献

[1] 高美娟, 于桂娜. 糖尿病性骨质疏松的相关危险因素研究进展[J]. 山东医药, 2008, 48(38): 110-111.
[2] 赵文昌, 宋丽军, 梁婷, 等. 糖尿病性骨质疏松的研究进展[J]. 现代中西医结合杂志, 2012, 21(35): 3984-3986.
[3] 顾同进, 竺越. 糖尿病性骨质疏松症的防治[J]. 老年医学与保健, 2005, 11(3): 192-193.
[4] 田安. 糖尿病性骨质疏松症试试中医疗法[J]. 糖尿病之友, 2019(10): 54-55.
[5] 董健. 糖尿病性骨质疏松症的发病机制[J]. 中国社区医师(医学专业), 2012, 14(2): 9-10.
[6] 甘利萍, 陈治卿, 蒋广恩, 等. 老年糖尿病并骨质疏松血胰岛素与骨钙素及PTH研究[J]. 中国骨质疏松杂志, 2008, 14(10): 700-703.
[7] 陈艺新, 郭涛, 尹培荣, 等. 血小板衍生性生长因子(PDGF)与胰岛素样生长因子I (IGF-I)对成骨细胞增殖及分化的影响[J]. 中华创伤骨科杂志, 2003, 5(4): 354-356.
[8] Yuan, S., Wan, Z., Cheng, S., Michaëlsson, K. and Larsson, S.C. (2021) Insulin-Like Growth Factor-1, Bone Mineral Density, and Fracture: A Mendelian Randomization Study. The Journal of Clinical Endocrinology & Metabolism, 106, 1552-1558. [Google Scholar] [CrossRef] [PubMed]
[9] Ouquerke, A. and Blulel, J. (2021) Osteoblasts and Insulin: An Overview. Journal of Biological Regulators and Homeostatic Agents, 35, 27-35.
[10] 舒强, 王桂兰. 骨质疏松与胰岛素样生长因子[J]. 国外医学(内分泌学分册), 2000, 20(1): 21-23.
[11] 王帅, 金磊, 海春旭, 等. PI3K/Akt信号通路在胰岛素抵抗中作用的研究进展[J]. 毒理学杂志, 2015, 29(4): 313-316.
[12] 粱军波, 徐春丽, 潘伟波, 等. 高血糖对成骨细胞增殖分化影响的实验研究[J]. 医学研究杂志, 2012, 41(3): 117-120.
[13] Shahen, V.A., Gerbaix, M., Koeppenkastrop, S., Lim, S.F., McFarlane, K.E., Nguyen, A.N.L., et al. (2020) Multifactorial Effects of Hyperglycaemia, Hyperinsulinemia and Inflammation on Bone Remodelling in Type 2 Diabetes Mellitus. Cytokine & Growth Factor Reviews, 55, 109-118. [Google Scholar] [CrossRef] [PubMed]
[14] 刘平, 马秀才, 傅德皓. 胰高血糖素样肽-1对骨质疏松症骨代谢影响的研究进展[J]. 中国医院药学杂志, 2015, 35(12): 1155-1157.
[15] 江帆, 陈小庄, 周晓莉, 等. 晚期糖基化终末产物､氧化低密度脂蛋白与老年糖尿病合并骨质疏松症的关系[J]. 检验医学, 2016, 31(10): 883-888.
[16] Park, S.Y., Choi, K.H., Jun, J.E. and Chung, H.Y. (2021) Effects of Advanced Glycation End Products on Differentiation and Function of Osteoblasts and Osteoclasts. Journal of Korean Medical Science, 36, e239. [Google Scholar] [CrossRef] [PubMed]
[17] 刘志民, 孙亮亮. 氧化应激在糖尿病发病机制中作用的认识[J]. 内科理论与实践, 2007, 2(3): 153-156.
[18] Scarpa, E., Antonelli, A., Balercia, G., Sabatelli, S., Maggi, F., Caprioli, G., et al. (2024) Antioxidant, Anti-Inflammatory, Anti-Diabetic, and Pro-Osteogenic Activities of Polyphenols for the Treatment of Two Different Chronic Diseases: Type 2 Diabetes Mellitus and Osteoporosis. Biomolecules, 14, Article 836. [Google Scholar] [CrossRef] [PubMed]
[19] 韩宝玲. 氧化应激在2型糖尿病及其并发症发病机制中的作用[J]. 实用临床医药杂志, 2011, 15(3): 122-124.
[20] Iantomasi, T., Romagnoli, C., Palmini, G., Donati, S., Falsetti, I., Miglietta, F., et al. (2023) Oxidative Stress and Inflammation in Osteoporosis: Molecular Mechanisms Involved and the Relationship with Micrornas. International Journal of Molecular Sciences, 24, Article 3772. [Google Scholar] [CrossRef] [PubMed]
[21] 汪四海, 方朝晖, 赵进东, 等. 复方补肾健脾活血颗粒对脾肾两虚夹瘀证糖尿病性骨质疏松患者的疗效及氧化应激､骨代谢的影响[J]. 中药药理与临床, 2021, 37(1): 198-203.
[22] 王芸, 闵玺, 王磊, 等. 合并非酒精性脂肪肝的老年2型糖尿病患者血清骨代谢与糖脂代谢关系分析[J]. 河北医药, 2024, 46(7): 1052-1055.
[23] Nomura, S., Kitami, A., Takao-Kawabata, R., Takakura, A., Nakatsugawa, M., Kono, R., et al. (2019) Teriparatide Improves Bone and Lipid Metabolism in a Male Rat Model of Type 2 Diabetes Mellitus. Endocrinology, 160, 2339-2352. [Google Scholar] [CrossRef] [PubMed]
[24] Natesan, V. and Kim, S. (2021) Lipid Metabolism, Disorders and Therapeutic Drugs-Review. Biomolecules & Therapeutics, 29, 596-604. [Google Scholar] [CrossRef] [PubMed]
[25] 刘军彤, 杨宇峰, 曹彬, 等. 糖尿病性骨质疏松症中医病因病机理论框架研究[J]. 辽宁中医药大学学报, 2019, 21(6): 110-113.
[26] 邴学震, 金智生. 糖尿病性骨质疏松的中医认识及临床治疗现状[J]. 中国中医基础医学杂志, 2019, 25(11): 1623-1626.
[27] 焦元元. 独活寄生汤加减治疗糖尿病性骨质疏松肝肾亏损证的临床研究[D]: [硕士学位论文]. 太原: 山西中医药大学, 2021.
[28] 王寅翎, 王彬. 基于络病理论运用络虚通补法治疗糖尿病骨质疏松[J]. 世界中医药, 2024, 19(4): 514-518.
[29] 金旭, 瞿锐, 周铖炜, 等. 芪精益肾健骨方联合碳酸钙D3片对肝肾亏损型糖尿病性骨质疏松症患者中医证候积分､骨密度及血清骨代谢指标的影响[J]. 现代生物医学进展, 2024, 24(15): 2858-2861+2872.
[30] 代俊泽, 刘毅, 廖翠平, 等. 中药组方治疗糖尿病合并骨质疏松症的用药规律挖掘及其作用机制的网络药理学与分子对接研究[J]. 中华中医药学刊, 2024, 42(12): 158-163+313-315.
[31] 楚淑芳, 赵恒侠, 刘德亮, 等. 糖尿病性骨质疏松的中医药防治[J]. 世界中医药, 2018, 13(7): 1804-1808+1812.
[32] 王文驰, 夏天, 武瑞骐, 等. 女贞子活性成分防治骨质疏松症的分子机制[J]. 中国组织工程研究, 2025, 29(18): 3856-3867.
[33] 王雯祎, 吴海帆, 蒋逸, 等. 中医治疗糖尿病性骨质疏松症的研究进展[J]. 中国现代医生, 2024, 62(9): 99-102.
[34] 孙立亚, 奚悦. 中药通过调控骨代谢相关信号通路治疗糖尿病骨质疏松的研究进展[J]. 中成药, 2022, 44(8): 2580-2586.
[35] 朱琦琦, 戴芳芳. 糖尿病性骨质疏松症的中医研究进展[J]. 中国骨质疏松杂志, 2019, 25(9): 1331-1335.
[36] 曹灵修, 任路, 张林. 中医药防治糖尿病骨质疏松症研究概述[J]. 山东中医杂志, 2020, 39(5): 525-529.
[37] 胡邵宁, 朱书渊, 魏燕斌. 温和灸结合穴位按摩治疗糖尿病性骨质疏松症临床研究[J]. 新中医, 2024, 56(17): 127-131.
[38] 胡芷萱. 壮骨通痹丸治疗糖尿病性骨质疏松症肝肾亏虚证的临床观察[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2023.
[39] 曲静, 张东鹏. 糖尿病性骨质疏松症中医药治疗研究进展[J]. 中国药物经济学, 2024, 19(8): 117-121.